A randomised, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of subcutaneous doses of ACV1 in patients with diabetic peripheral neuropathic pain or post-herpetic neuralgia.
Phase of Trial: Phase II
Latest Information Update: 13 Jul 2016
At a glance
- Drugs ACV 1 (Primary)
- Indications Diabetic neuropathies; Neuropathic pain; Postherpetic neuralgia
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Calzada
- 17 Oct 2006 New trial record.